Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of “Buy” from Brokerages

Vera Therapeutics, Inc. (NASDAQ:VERA) has been given an average recommendation of “Buy” by the ten research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $53.89.

A number of research analysts have weighed in on VERA shares. Guggenheim boosted their target price on shares of Vera Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research report on Monday, October 28th. JPMorgan Chase & Co. boosted their price objective on Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a research report on Tuesday. Evercore ISI raised Vera Therapeutics to a “strong-buy” rating in a report on Monday, September 16th. Scotiabank started coverage on Vera Therapeutics in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 price target for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $107.00 price objective on shares of Vera Therapeutics in a research note on Tuesday, October 1st.

Insider Buying and Selling

In other news, CEO Marshall Fordyce sold 15,625 shares of the firm’s stock in a transaction dated Wednesday, September 11th. The shares were sold at an average price of $37.50, for a total transaction of $585,937.50. Following the completion of the transaction, the chief executive officer now directly owns 307,972 shares of the company’s stock, valued at approximately $11,548,950. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Vera Therapeutics news, Director Beth C. Seidenberg sold 1,177 shares of the company’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $42.01, for a total value of $49,445.77. Following the sale, the director now directly owns 160,376 shares in the company, valued at $6,737,395.76. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Marshall Fordyce sold 15,625 shares of the stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $37.50, for a total value of $585,937.50. Following the transaction, the chief executive officer now owns 307,972 shares of the company’s stock, valued at $11,548,950. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 104,398 shares of company stock valued at $4,376,163 over the last ninety days. 21.70% of the stock is owned by company insiders.

Institutional Trading of Vera Therapeutics

Several hedge funds have recently modified their holdings of the company. Victory Capital Management Inc. grew its position in Vera Therapeutics by 13.5% during the 3rd quarter. Victory Capital Management Inc. now owns 38,253 shares of the company’s stock worth $1,691,000 after acquiring an additional 4,546 shares during the last quarter. Chartwell Investment Partners LLC boosted its stake in Vera Therapeutics by 63.5% in the third quarter. Chartwell Investment Partners LLC now owns 19,172 shares of the company’s stock worth $847,000 after purchasing an additional 7,447 shares in the last quarter. AlphaCentric Advisors LLC bought a new stake in shares of Vera Therapeutics during the third quarter worth $332,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Vera Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,545 shares of the company’s stock worth $466,000 after purchasing an additional 4,118 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Vera Therapeutics by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock valued at $86,000 after buying an additional 350 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Stock Up 0.5 %

VERA opened at $47.94 on Thursday. The firm has a market cap of $2.63 billion, a P/E ratio of -21.69 and a beta of 1.03. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.43 and a current ratio of 21.43. The business has a 50 day moving average price of $40.86 and a 200 day moving average price of $38.97. Vera Therapeutics has a twelve month low of $9.99 and a twelve month high of $50.78.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). Research analysts forecast that Vera Therapeutics will post -2.57 EPS for the current year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.